Bristol-Myers Squibb
New York-based company Bristol-Myers Squibb made the news in recent years for its big acquisition decision, specifically in October 2020, when it acquired biopharmaceutical brand MyoKardia for $13.1 billion in a bid to boost its cardiovascular franchise with the drug Mavacamten. This certainly was a good sign for investors, including Blue Rock Advisors.
The Wayzata, Minnesota-based hedge fund has been cashing in on several healthcare companies despite the pandemic wreaking havoc on some sectors in the third quarter of 2020. It purchased 126,767 shares in Bristol-Myers Squibb, which accounted for 6.6 percent of the firm’s holdings.
